Latest news with #AIChemistryPlatform
Yahoo
2 days ago
- Business
- Yahoo
Juvenescence enhances AI drug discovery with Ro5 acquisition
Juvenescence has acquired drug discovery company Ro5, a move that enhances its AI/machine learning capabilities and improves research and development capabilities. The acquisition forms a key part of Juvenescence's partnership with the Abu Dhabi global healthcare company M42, which was announced in April 2025. Ro5's platform utilises a biomedical knowledge graph containing more than 85 million nodes and 400m relationships to find new connections in biological processes and enable evaluation of drug targets based on therapeutic, biological and market potential. Ro5's AI Chemistry Platform also uses advanced machine learning models and cheminformatics tools for quick compound discovery and design from hit identification to lead optimisation. Juvenescence CBE and CEO Dr Richard Marshall stated: 'We are delighted to welcome the Ro5 team and the company's capabilities into Juvenescence. The addition of Ro5's AI platform significantly enhances our drug discovery capabilities, accelerating our efforts to identify and advance effective therapeutics to extend healthspan. 'This acquisition is also a critical part of our wider strategy with M42 to deliver a pipeline of transformative therapies and establish a world-class life sciences hub in Abu Dhabi. Together, we remain committed to improving the lives of millions of patients.' The acquisition follows the recent announcement by Juvenescence of a $76m first close of its Series B-1 financing round, led by investor M42. Follow-on investments came from existing investors, with the second close anticipated in the third quarter of 2025. The funds will support clinical milestones along with AI-driven development across Juvenescence's portfolio, targeting diseases related to ageing. Incorporating Ro5's AI platform into Juvenescence is expected to accelerate the development of AI-enabled treatments. This integration will reinforce Juvenescence's pipeline in cardio-metabolism, cognition, immunity and cellular repair sectors. Ro5 CEO Charles Dazler Knuff added: 'Together with our partners at M42, we are laying the foundations for a pioneering life sciences ecosystem in Abu Dhabi that leverages AI innovation to transform patient care and global health outcomes.' "Juvenescence enhances AI drug discovery with Ro5 acquisition" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Business
- Yahoo
Juvenescence acquires AI drug discovery company Ro5 to boost R&D capabilities and drive pipeline of medicines to extend healthy lifespan
Ro5 Inc. acquisition enhances artificial intelligence/machine learning drug discovery capabilities Strategic addition strengthens Juvenescence's AI-enabled therapeutics pipeline and supports partnership with M42 (Mubadala) Acquisition follows $76m Series B-1 financing first-close led by M42 in May 2025 Ramsey, Isle of Man, 5 June 2025: Juvenescence Limited, a clinical stage AI-enabled biotech company, is pleased to announce the acquisition of Ro5 Inc., a proprietary AI drug discovery company. This acquisition enhances Juvenescence's artificial intelligence/machine learning drug discovery capabilities and forms a central component of its strategic partnership with Abu Dhabi-based global healthcare company M42, announced in April 2025. Ro5's platform leverages a proprietary Biomedical Knowledge Graph, comprising over 85 million nodes and approximately 400 million relationships, to uncover novel associations in biological processes and enable a robust evaluation of drug targets based on biological, therapeutic, and market potential. The Company's AI Chemistry Platform incorporates state-of-the art machine learning model and cheminformatics tools, facilitating rapid and efficient discovery and design of novel compounds from hit identification through to lead optimisation. The acquisition of Ro5 follows Juvenescence's recent announcement of a $76 million first-close of its Series B-1 financing round led by cornerstone investor M42, with follow-on investments from existing investors. The second close of the Series B-1 is anticipated in the third quarter of 2025. Proceeds will support clinical milestones and AI-driven development across Juvenescence's portfolio of therapeutics targeting age-related diseases. The integration of Ro5's AI drug discovery platform and expert team into Juvenescence will accelerate the identification and development of AI-enabled therapeutics, reinforcing the company's growing pipeline in cognition, cardio-metabolism, immunity, and cellular Richard Marshall CBE, CEO of Juvenescence, said: 'We are delighted to welcome the Ro5 team and the Company's capabilities into Juvenescence. The addition of Ro5's AI platform significantly enhances our drug discovery capabilities, accelerating our efforts to identify and advance effective therapeutics to extend healthspan. This acquisition is also a critical part of our wider strategy with M42 to deliver a pipeline of transformative therapies and establish a world-class life sciences hub in Abu Dhabi. Together, we remain committed to improving the lives of millions of patients.' Charles Dazler Knuff, CEO of Ro5, added: 'The Ro5 team are thrilled to be joining the world class drug development team at Juvenescence. Embedding our AI-driven drug discovery capabilities into Juvenescence's operations will accelerate their ability to advance next-generation therapeutics. Together with our partners at M42 we are also laying the foundations for a pioneering life sciences ecosystem in Abu Dhabi that leverages AI innovation to transform patient care and global health outcomes.' About Juvenescence Juvenescence is a clinical-stage AI-enabled biotech company developing novel medicines to extend healthy lifespan. Our approach centers around developing medicines that target core aging mechanisms to treat and prevent age-related diseases. It was founded by Jim Mellon, Dr Greg Bailey and Dr Declan Doogan – with a track record of leading 2 of the 10 largest biopharma deals in the last decade, including the sale of Biohaven to Pfizer for $11.6bn. The Juvenescence team, led by Dr Richard Marshall CBE, consists of world-class R&D leadership that have previously been instrumental in the approval of medicines totalling $30bn in peak annual sales. Powered by an unrivaled drug development team, Juvenescence leverages cutting-edge AI tools to unlock successful therapeutics. The company's diverse, AI-enabled medicines pipeline of clinical and near-clinical stage candidates targeting core ageing mechanisms are in development for cognition, cardio-metabolism, immunity and cellular repair. In addition, Juvenescence has investments in a number of cutting-edge companies and platform technologies focused on AI and regenerative medicine. For more information, visit: About Ro5 In the race to save and improve lives, Ro5 accelerates drug discovery, development, repurposing, and clinical trials. We enrich our client's data with our proprietary database, then use machine learning platforms to reduce discovery time from years to months, increase accuracy, and, at every point, lower costs. Our proprietary state-of-the-art neural network architectures learn the complex relationships between a molecule's basic physicochemical properties and its more general pharmacological characteristics and are real and effective. Investor Relations Contact: juvenescenceir@ Media contact: ICR Healthcare Jessica Hodgson / Chris Welsh Juvenescence@ Forward-Looking Statements Statements in this communication relating to plans, strategies, specific activities, and other statements that are not descriptions of historical facts are forward-looking statements. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include any risks detailed from time to time in the Company's reports. Such statements are based on the management's current beliefs and expectations and are subject to significant risks and uncertainties outside of management and the Company's control. Given these uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as otherwise required by law, the Company does not undertake any obligation, and expressly disclaims any obligation, to update, alter or otherwise revise any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future events or otherwise.
Yahoo
4 days ago
- Business
- Yahoo
Juvenescence acquires AI drug discovery company Ro5 to boost R&D capabilities and drive pipeline of medicines to extend healthy lifespan
Ro5 Inc. acquisition enhances artificial intelligence/machine learning drug discovery capabilities Strategic addition strengthens Juvenescence's AI-enabled therapeutics pipeline and supports partnership with M42 (Mubadala) Acquisition follows $76m Series B-1 financing first-close led by M42 in May 2025 Ramsey, Isle of Man, 5 June 2025: Juvenescence Limited, a clinical stage AI-enabled biotech company, is pleased to announce the acquisition of Ro5 Inc., a proprietary AI drug discovery company. This acquisition enhances Juvenescence's artificial intelligence/machine learning drug discovery capabilities and forms a central component of its strategic partnership with Abu Dhabi-based global healthcare company M42, announced in April 2025. Ro5's platform leverages a proprietary Biomedical Knowledge Graph, comprising over 85 million nodes and approximately 400 million relationships, to uncover novel associations in biological processes and enable a robust evaluation of drug targets based on biological, therapeutic, and market potential. The Company's AI Chemistry Platform incorporates state-of-the art machine learning model and cheminformatics tools, facilitating rapid and efficient discovery and design of novel compounds from hit identification through to lead optimisation. The acquisition of Ro5 follows Juvenescence's recent announcement of a $76 million first-close of its Series B-1 financing round led by cornerstone investor M42, with follow-on investments from existing investors. The second close of the Series B-1 is anticipated in the third quarter of 2025. Proceeds will support clinical milestones and AI-driven development across Juvenescence's portfolio of therapeutics targeting age-related diseases. The integration of Ro5's AI drug discovery platform and expert team into Juvenescence will accelerate the identification and development of AI-enabled therapeutics, reinforcing the company's growing pipeline in cognition, cardio-metabolism, immunity, and cellular Richard Marshall CBE, CEO of Juvenescence, said: 'We are delighted to welcome the Ro5 team and the Company's capabilities into Juvenescence. The addition of Ro5's AI platform significantly enhances our drug discovery capabilities, accelerating our efforts to identify and advance effective therapeutics to extend healthspan. This acquisition is also a critical part of our wider strategy with M42 to deliver a pipeline of transformative therapies and establish a world-class life sciences hub in Abu Dhabi. Together, we remain committed to improving the lives of millions of patients.' Charles Dazler Knuff, CEO of Ro5, added: 'The Ro5 team are thrilled to be joining the world class drug development team at Juvenescence. Embedding our AI-driven drug discovery capabilities into Juvenescence's operations will accelerate their ability to advance next-generation therapeutics. Together with our partners at M42 we are also laying the foundations for a pioneering life sciences ecosystem in Abu Dhabi that leverages AI innovation to transform patient care and global health outcomes.' About Juvenescence Juvenescence is a clinical-stage AI-enabled biotech company developing novel medicines to extend healthy lifespan. Our approach centers around developing medicines that target core aging mechanisms to treat and prevent age-related diseases. It was founded by Jim Mellon, Dr Greg Bailey and Dr Declan Doogan – with a track record of leading 2 of the 10 largest biopharma deals in the last decade, including the sale of Biohaven to Pfizer for $11.6bn. The Juvenescence team, led by Dr Richard Marshall CBE, consists of world-class R&D leadership that have previously been instrumental in the approval of medicines totalling $30bn in peak annual sales. Powered by an unrivaled drug development team, Juvenescence leverages cutting-edge AI tools to unlock successful therapeutics. The company's diverse, AI-enabled medicines pipeline of clinical and near-clinical stage candidates targeting core ageing mechanisms are in development for cognition, cardio-metabolism, immunity and cellular repair. In addition, Juvenescence has investments in a number of cutting-edge companies and platform technologies focused on AI and regenerative medicine. For more information, visit: About Ro5 In the race to save and improve lives, Ro5 accelerates drug discovery, development, repurposing, and clinical trials. We enrich our client's data with our proprietary database, then use machine learning platforms to reduce discovery time from years to months, increase accuracy, and, at every point, lower costs. Our proprietary state-of-the-art neural network architectures learn the complex relationships between a molecule's basic physicochemical properties and its more general pharmacological characteristics and are real and effective. Investor Relations Contact: juvenescenceir@ Media contact: ICR Healthcare Jessica Hodgson / Chris Welsh Juvenescence@ Forward-Looking Statements Statements in this communication relating to plans, strategies, specific activities, and other statements that are not descriptions of historical facts are forward-looking statements. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include any risks detailed from time to time in the Company's reports. Such statements are based on the management's current beliefs and expectations and are subject to significant risks and uncertainties outside of management and the Company's control. Given these uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as otherwise required by law, the Company does not undertake any obligation, and expressly disclaims any obligation, to update, alter or otherwise revise any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future events or otherwise.
